Neon Therapeutics Inc. (NTGN) and Evogene Ltd. (NASDAQ:EVGN) Comparing side by side

Since Neon Therapeutics Inc. (NASDAQ:NTGN) and Evogene Ltd. (NASDAQ:EVGN) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neon Therapeutics Inc. 2 -0.02 15.57M -3.01 0.00
Evogene Ltd. 2 0.00 23.06M -0.74 0.00

In table 1 we can see Neon Therapeutics Inc. and Evogene Ltd.’s top-line revenue, earnings per share and valuation.


Table 2 provides us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Neon Therapeutics Inc. 873,296,314.99% -76% -68.2%
Evogene Ltd. 1,510,843,215.62% 0% 0%

Analyst Ratings

Ratings and Recommendations for Neon Therapeutics Inc. and Evogene Ltd. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Neon Therapeutics Inc. 0 0 1 3.00
Evogene Ltd. 0 0 0 0.00

Neon Therapeutics Inc.’s upside potential currently stands at 1,200.00% and an $13 consensus target price.

Institutional & Insider Ownership

The shares of both Neon Therapeutics Inc. and Evogene Ltd. are owned by institutional investors at 69.8% and 0% respectively. Neon Therapeutics Inc.’s share held by insiders are 3.8%.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Neon Therapeutics Inc. -18.52% -37.69% -53.27% -36.44% -74.73% -43.14%
Evogene Ltd. 0.5% -11.14% -34.36% -28.56% -51.9% -26.4%

For the past year Neon Therapeutics Inc.’s stock price has bigger decline than Evogene Ltd.


Evogene Ltd. beats Neon Therapeutics Inc. on 8 of the 11 factors.

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Evogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States and Germany. It operates through two segments, Evogene and Evofuel. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants, which include microbial-based products that are applied externally to the plant for yield enhancement. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced species of the castor bean plant to serve as a source of feedstock for biofuel and other industrial uses. The company has strategic collaborations with various agricultural companies, including BASF, Bayer, DuPont, Monsanto, and Syngenta that cover 24 products in various stages of development. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.